Kenvue Inc. (KVUE)

US — Consumer Defensive Sector
Peers:

Automate Your Wheel Strategy on KVUE

With Tiblio's Option Bot, you can configure your own wheel strategy including KVUE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol KVUE
  • Rev/Share 7.9948
  • Book/Share 5.2524
  • PB 4.5446
  • Debt/Equity 0.8692
  • CurrentRatio 0.8566
  • ROIC 0.08

 

  • MktCap 45828249313.0
  • FreeCF/Share 0.7576
  • PFCF 31.6057
  • PE 43.2644
  • Debt/Assets 0.3328
  • DivYield 0.0344
  • ROE 0.1042

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation KVUE Redburn Atlantic -- Neutral -- $23.5 April 10, 2025
Initiation KVUE Evercore ISI -- In-line -- $25 March 24, 2025
Upgrade KVUE Piper Sandler Neutral Overweight $21 $26 Jan. 6, 2025
Downgrade KVUE Deutsche Bank Buy Hold $25 $24 Dec. 12, 2024
Initiation KVUE Jefferies -- Buy -- $27 Sept. 24, 2024
Downgrade KVUE RBC Capital Mkts Outperform Sector Perform -- $24 Sept. 24, 2024

News

Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference
KVUE
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Thibaut Mongon, Chief Executive Officer, Amit Banati, Chief Financial Officer, and Carlton Lawson, Group President, Europe, Middle East and Africa & Latin America will participate in a fireside chat on Tuesday, June 3, 2025, at 6:00 a.m.

Read More
image for news Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference
Moody's U.S. Debt Downgrade: Stocks Poised To Benefit
AAL, AAPL, CCL, CUK, F, GM, GOOG, GOOGL, JNJ, KVUE, MSFT, UAL
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive

Corporations play a vital and often benevolent role in capitalist societies, supporting economic growth and innovation with more conservative balance sheets than their governments. Microsoft, Apple and Johnson & Johnson hold Moody's highest credit rating of Aaa, reflecting exceptional financial strength and stability. Alphabet and Berkshire Hathaway are rated Aa2 by Moody's, indicating very high credit quality, just below the top tier.

Read More
image for news Moody's U.S. Debt Downgrade: Stocks Poised To Benefit
Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript
KVUE
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Kenvue, Inc. (NYSE:KVUE ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Sofya Tsinis - Head of Investor Relations Thibaut Mongon - Chief Executive Officer and Director Paul Ruh - Chief Financial Officer Conference Call Participants Bonnie Herzog - Goldman Sachs Peter Grom - UBS Andrea Teixeira - J.P. Morgan Anna Lizzul - Bank of America Keith Davis - Jefferies Nik Modi - RBC Capital Markets Filippo Falorni - Citi Javier Escalante - Evercore ISI Alec Legg - Canaccord Genuity Steve Powers - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Operator Hello, and welcome to …

Read More
image for news Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript
Compared to Estimates, Kenvue (KVUE) Q1 Earnings: A Look at Key Metrics
KVUE
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Kenvue (KVUE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Compared to Estimates, Kenvue (KVUE) Q1 Earnings: A Look at Key Metrics
Kenvue Boosts 2025 Sales Growth View
KVUE
Published: May 08, 2025 by: WSJ
Sentiment: Positive

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth projection for the year, while warning that foreign exchange would weigh on adjusted earnings.

Read More
image for news Kenvue Boosts 2025 Sales Growth View
Kenvue (KVUE) Beats Q1 Earnings and Revenue Estimates
KVUE
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

Kenvue (KVUE) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.28 per share a year ago.

Read More
image for news Kenvue (KVUE) Beats Q1 Earnings and Revenue Estimates
Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Sales Outlook
KVUE
Published: May 08, 2025 by: Investopedia
Sentiment: Positive

Shares of Kenvue (KVUE) rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates.

Read More
image for news Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Sales Outlook
Kenvue stock climbs as second quarter comes in ahead of forecasts
KVUE
Published: May 08, 2025 by: Proactive Investors
Sentiment: Positive

Consumer brands firm Kenvue Inc (NYSE:KVUE) traded on the front foot in Thursday's early deals, as its second quarter beat expectations (but, fell short in year-over-year comparatives). Net sales totalled $3.74 billion in Kenvue's first quarter, exceeding the consensus forecast of $3.68 billion whilst 3.9% lower than last year's digit.

Read More
image for news Kenvue stock climbs as second quarter comes in ahead of forecasts
Kenvue first-quarter results beat estimates on strength in self care unit
KVUE
Published: May 08, 2025 by: Reuters
Sentiment: Positive

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self-care products including cough and cold medicines Tylenol and Benadryl helped offset a fall in demand for its skin health and beauty products.

Read More
image for news Kenvue first-quarter results beat estimates on strength in self care unit
Kenvue Announces Chief Financial Officer Transition
KVUE
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a.

Read More
image for news Kenvue Announces Chief Financial Officer Transition
Buy 3 "Safer" Dividend Kings Of 25 From May's 55
ADM, ADP, BDX, BKH, CDUAF, CWT, ED, FRT, FTS, HRL, KO, KVUE, MO, MSEX, NFG, NWN, PEP, PPG, RLI, SCL, SWK, SYY, TGT, UBSI, UVV
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive

The May collection of Dividend Kings grew to 55, with Automatic Data Processing and RLI Corporation joining, despite two companies dropping off for not increasing dividends. Six top-yield Dividend Kings, including Altria and Canadian Utilities, are now fairly priced, with annual dividends from $1K investments exceeding their single-share prices. Analysts predict net gains of 14.7% to 56.86% for the top ten Dividend Kings by yield for the coming year, based on target prices. Among the 55 Dividend Kings, 16 show negative free cash flow margins, making them cash-poor and unsafe for investment.

Read More
image for news Buy 3 "Safer" Dividend Kings Of 25 From May's 55
Kenvue (KVUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
KVUE
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Kenvue (KVUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Kenvue (KVUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Two Stocks To Consider During Market Unrest To Provide Income Stability
BUD, JAPAY, JNJ, KVUE, MO, PM, XLF, XLK, XLP, XLV
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Positive

Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price stability and a 3.59% dividend yield, despite potential headwinds from tariffs and economic slowdown. Altria Group, with its 7% yield and Dividend King status, provides stability and potential upside during economic uncertainty, leveraging its pricing power and recession-proof products.

Read More
image for news Two Stocks To Consider During Market Unrest To Provide Income Stability
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
KVUE
Published: February 21, 2025 by: The Motley Fool
Sentiment: Neutral

Kenvue (KVUE 0.54%) stock is down since completing its spin-off from Johnson & Johnson (JNJ 1.13%) in August 2023. But with more than a year of results now in the books, investors have had time to acclimate to Kenvue as an independent entity.

Read More
image for news Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
KVUE
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive

Kenvue, spun off from Johnson & Johnson, shows potential as a solid dividend stock post-2025 despite current economic challenges and recent earnings misses. The company boasts strong brands like Tylenol and Listerine, and management's cost-cutting initiatives aim to save $350 million by 2026. Kenvue's valuation and growth prospects make it attractive for long-term dividend investors, but cash flow headwinds warrant a hold rating for now.

Read More
image for news Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
KVUE
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 19, 2025, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. i.

Read More
image for news Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
Kenvue: An Intriguing Turnaround
KVUE
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral

Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand portfolio, including Tylenol and Band-Aid, suggests potential for a turnaround, supported by activist investor Starboard Value. Execution issues, external factors, and potential structural changes have impacted Kenvue's performance, but improvements in marketing and management could drive future growth.

Read More
image for news Kenvue: An Intriguing Turnaround

About Kenvue Inc. (KVUE)

  • IPO Date 2023-05-04
  • Website https://www.kenvue.com
  • Industry Household & Personal Products
  • CEO Mr. Thibaut Mongon
  • Employees 22000

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.